Myron Levin
Pediatric Infectious Diseases · Aurora, CONPI 1306920038
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $210,998 of the $291,777 with a category attached, or 72.3%. It is spread thinly across 16 manufacturers, the largest accounting for just 20.4%. Among pediatric infectious diseases clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 213 payments — averaging $1369.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$60K
- Pfizer$59K
- AstraZeneca$31K
- Seqirus USA Inc$30K
- Merck$23K
- Astrazeneca UK Limited$19K
- plus $70K from 10 others
Across 216 payments — averaging $20,788 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$2.5M
- GSK$1.7M
- Janssen Research & Development, LLC$163K
- Merck$85K
- Saol International Limited$48K
- Pfizer$26K
- plus $8K from 1 others
What the payments were for
- Consulting fees$210,99872%
- Speaking & faculty fees$49,28017%
- Travel & lodging$26,4339%
- Food & beverage$5,0162%
- Education$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 61 | $59,555 |
| Pfizer(2 entities) | 42 | $59,303 |
| AstraZeneca | 7 | $31,432 |
| Seqirus USA Inc | 17 | $30,236 |
| Merck | 22 | $22,941 |
| Astrazeneca UK Limited | 14 | $18,522 |
| Modernatx, Inc. | 16 | $16,714 |
| Dynavax Technologies Corporation | 13 | $15,075 |
| Sanofi Pasteur Inc. | 3 | $13,165 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $5,288 |
| Sobi, Inc | 7 | $5,218 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $4,140 |
| Bavarian Nordic A/s | 1 | $3,250 |
| Genentech, Inc. | 1 | $2,813 |
| Janssen Scientific Affairs, LLC | 1 | $2,500 |
| Saol Therapeutics Inc. | 2 | $1,625 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Heplisav-B$14,325
- BEXSERO$9,992
- PREVNAR 20$7,550
- SHINGRIX$5,888
- FLUMIST QUADRIVALENT$5,773
- Synagis$5,108
- FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL)$4,079
- PREVNAR - 13$2,450
- COMIRNATY$2,100
- ABRYSVO$2,025
- FLUMIST$1,611
- EVUSHELD$1,227
How this compares
$291,777 in reported general payments places this provider in the 90th percentile of 20 pediatric infectious diseases providers in Colorado.
See all pediatric infectious diseases providers in Colorado →
Other pediatric infectious diseases in Aurora
- Eric SimoesAurora$531K
- Edwin AsturiasAurora$42K
- Samuel DominguezAurora$21K
- Daniel OlsonAurora$18K
- Mary GlodeAurora$13K
- Ann NyquistAurora$8K
- Elizabeth McFarlandAurora$3K
- Kevin MessacarAurora$3K
- Christina Smith-AndersonAurora$268
- Michael BozzellaAurora$125
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.